Topics
Business & Finance
-
Friday - May 24, 2013
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant » more
-
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) » more
-
Friday - May 17, 2013
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan » more
-
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Initiates Phase III Trial of Regorafenib in Patients with Advanced Liver Cancer » more
-
Tuesday - May 7, 2013
Not intended for UK Media
Bayer commences cash tender offer for all outstanding shares of Conceptus, Inc. » more
-
Tuesday - May 7, 2013
Sustainable Development Report 2012:
Bayer documents economic, social and ecological performance
Bayer CEO Dekkers: “Innovation and sustainability are the driving force behind our business success” / Integrated reporting from 2014 » more
-
Monday - April 29, 2013
Not intended for UK media - Strategic expansion of Women’s Health business:
Bayer to acquire Conceptus, Inc.
Adds Essure®, the only non-surgical permanent birth control method, to Bayer’s contraception portfolio » more
-
Friday - April 26, 2013
Annual Stockholders' Meeting 2013 » more
-
Friday - April 26, 2013
Dr. Marijn Dekkers at the Annual Stockholders’ Meeting of Bayer AG:
“Bayer is a world-class innovation company”
2012 operationally a very successful year / Highest sales in the company’s 150-year history / Proposal to raise dividend for 2012 to EUR 1.90 per share / Employees to benefit from the company’s success with bonuses totaling over EUR 700 million / Life Sciences off to a good start in anniversary year » more
-
Thursday - April 25, 2013
First quarter of 2013:
Bayer: Life Sciences off to a good start in anniversary year
New pharmaceutical products spur growth at HealthCare, continuing strong development at CropScience, cost pressure at MaterialScience / Group sales up 2.1 percent to EUR 10,266 million / EBIT improves by 8.6 percent to EUR 1,771 million / EBITDA before special items increased by 0.4 percent to EUR 2,453 million / Net income rises 11.5 percent to EUR 1,160 million / Gratifying development in Emerging Markets / Group outlook for 2013 confirmed » more
-
Monday - April 8, 2013
Not intended for U.S. and UK Media
U. S. FDA Grants Priority Review to Bayer’s Riociguat for the Treatment of two Life-Threatening Pulmonary Hypertension Indications » more
-
Monday - March 25, 2013
Not intended for U.S. and UK Media
Bayer’s Stivarga® (regorafenib) Tablets Approved in Japan for the Treatment of Advanced or Recurrent Colorectal Cancer » more
-
Friday - March 22, 2013
Not intended for U.S. and UK Media - Acute Coronary Syndrome (ACS)
Bayer’s Xarelto® (Rivaroxaban) Recommended for Approval in the EU for the Prevention of Atherothrombotic Events after an ACS
Xarelto 2.5 mg twice-daily (BID) demonstrated significant clinical benefit for patients with ACS when used with standard antiplatelet therapy / Complementary modes of action of Xarelto 2.5 mg BID and antiplatelet therapy have the potential to provide more complete protection against long-term clot formation / Final decision from the European Commission expected in the first half of 2013 » more
-
Tuesday - March 5, 2013
Not intended for U.S. and UK Media: Acute Coronary Syndrome (ACS):
U.S. FDA Issues Complete Response Letter for Bayer’s Xarelto® (Rivaroxaban) for the Reduction of Cardiovascular Events in Patients with ACS » more
-
Thursday - February 28, 2013
Financial News Conference
Full Year 2012 Results » more
-
Thursday - February 28, 2013
New products create optimism for the future
Bayer: continuing growth momentum
Group targets achieved in 2012 – sales and earnings before special items increase in all subgroups / Sales increase by 8.8 percent to EUR 39,760 million / EBIT EUR 3,960 million (minus 4.6 percent) – Net income EUR 2,446 million (minus 1.0 percent) / Further accounting measures for legal claims / EBITDA before special items rises by 8.8 percent to EUR 8,284 million / Core earnings per share improve by 10.8 percent to EUR 5.35 / Encouraging growth in the emerging markets / Steady progress with innovation pipeline strengthens life-science businesses / Forecast for anniversary year 2013: continuing record development » more
-
Tuesday - February 26, 2013
Bayer proposes dividend increase to EUR 1.90 per share for 2012
Payout up 15 percent to EUR 1,571 million » more
-
Tuesday - February 26, 2013
Not Intended for U.S. and U.K. Media
Bayer’s Regorafenib Granted Priority Review in Japan for the Treatment of Patients with Gastrointestinal Stromal Tumors » more
Copyright @ Bayer AG
Search
Publications
research – The Bayer Scientific Magazine
Stockholders' Newsletter
Annual Report
Sustainable Development Report
Publications Overview
Newsletter
Events
Download Center - Selection